Marisa Wexler, MS,  senior science writer—

Participants in a Phase 2 trial testing Algernon Pharmaceuticals’ NP-120 (ifenprodil) in people with chronic cough associated with idiopathic pulmonary fibrosis (IPF) have asked to have the experimental medication for their personal use, Algernon announced. The company noted in a press release that it’s “not making any express or…

Treatment with metformin, a medication commonly used to lower blood sugar levels in people with diabetes, was associated with a significantly lower risk of death or hospitalization in patients with diabetes and idiopathic pulmonary fibrosis (IPF), according to a study based on insurance data. The study, “Evaluation for…

The U.S. Food and Drug Administration (FDA) has given permission for Angion Biomedica to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with idiopathic pulmonary fibrosis (IPF). Angion is planning to launch the trial soon and expects that results will be…

Sandoz has launched a generic version of Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF) in the U.S. The new generic is available now via specialty pharmacies and there is a $0 co-pay program for eligible patients, according to Sandoz. “Sandoz is putting patients first…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLN-74809, now in a Phase 2 clinical trial, as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is intended to help speed the development of treatments aiming to address unmet medical needs for serious…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Angion Biomedica plans to ask the U.S. Food and Drug Administration (FDA) for permission to start testing its experimental therapy ANG-3070 in people with idiopathic pulmonary fibrosis (IPF), the company announced. ANG-3070 is an oral medication designed to block the activity of multiple protein receptors that contribute to…

Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…

RXC007, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF) being developed by Redx Pharma, continues to be safe and well-tolerated in a Phase 1 study in healthy volunteers, the company reported. “Clinical data from our Phase 1 study suggests that RXC007 is safe and well-tolerated at the drug doses…

Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…